Prognostic significance of catestatin in patients with primary hypertension and type 2 diabetes mellitus

Abstract

The aim of this study was to determine predictors of cardiovascular complications of arterial hypertension (AH) and type 2 diabetes mellitus (T2DM) and investigate the prognostic potential of catestatin (CST) and relaxin-2 (RLN-2) in this patient population. Materials and methods. The research was performed in accordance with all ethical principles of the Declaration of Helsinki. All study participants signed a written informed consent. This study involved 106 patients with primary hypertension and 30 healthy volunteers. 55 hypertensive patients had comorbid T2DM. Plasma CST and RLN-2 levels were measured by an enzyme-linked immunosorbent assay. Major adverse cardiovascular events (MACE) were collected during 12-month follow-up via telephone interviews at visits in months 3, 6, 9, and 12. The end points of this study were acute myocardial infarction, ischemic stroke, acute heart failure and cardiac death. Statistical data analysis was performed using the SPSS 25.0 statistical software. Results. 13 end-points were registered in patients with AH during the 12-month follow-up period, but the difference in frequency of MACE occurrence between patients with AH and T2DM and hypertensive patients without T2DM was insignificant (p=0.181). The Cox proportional hazard model indicated CST (p=0.01), but not RLN-2 (p=0.20), as an independent predictor of MACE in hypertensive patients. Age (p=0.01), AH duration (p=0.03), presence of T2DM (p=0.03), HOMA-IR index (p=0.02), insulin (p=0.02) and uric acid levels (p=0.02) were also established as independent factors of end-points occurrence. Conclusions. CST is an independent factor for predicting cardiovascular complications of AH, which allows us to consider it as a prognostic biomarker in patients with AH, especially hypertensive patients with comorbidity T2DM